Value-based agreements for acute hepatic porphyria therapy Givlaari launch

Alnylam Pharmaceuticals announced a new and enhanced framework for value-based agreements designed to provide access to the recently FDA-approved Givlaari for patients with acute hepatic porphyria, according to a press release.

Alnylam is in active discussions with leading payers about such value-based agreements for Givlaari (givosiran) and Alnylam has reached an agreement in principle with Harvard Pilgrim.

“Patients can sometimes experience lengthy delays waiting for access when a new medicine becomes available, as payers can be challenged to determine both which patients may best respond and the number of potentially undiagnosed patients in their plans,” Barry Greene, president of Alnylam Pharmaceuticals, said in the release. “Our proactive approach with VBAs is intended to act as ‘insurance for insurers’ and builds upon our Alnylam Patient Access Philosophy to do everything we can to accelerate patient access to innovative medicines at a sustainable rate to the health care system.”

As part of the new framework, participating government and commercial payers will pay the full value for givosiran when the therapy delivers patient outcomes in real-world settings that are comparable with clinical trial results. Additionally, a newly designed “Prevalence-Based Adjustment” feature will trigger rebates to participating payers if the number of diagnosed patients they cover exceeds current epidemiologic estimates for acute hepatic porphyria.

"Harvard Pilgrim applauds Alnylam’s efforts to help us manage plan members’ costs if the number of patients treated exceeds initial forecasts based upon existing prevalence models,” Michael Sherman, MD, chief medical officer at Harvard Pilgrim, said. “This prevalence-based adjustment framework may become a model approach for ultra-rare diseases where few or no therapies have previously existed and where diagnosis rates are uncertain.”

Reference: www.alnylam.com